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The amyloidogenic peptide Aβ plays a key role in Alzheimer’s disease (AD) forming
insoluble aggregates in the brain. The peptide shares its amyloidogenic properties with
amylin that forms aggregates in the pancreas of patients with Type 2 Diabetes mellitus
(T2DM). While epidemiological studies establish a link between these two diseases, it is
becoming increasingly clear that they also share biochemical features suggesting common
pathogenic mechanisms. We discuss commonalities as to how Aβ and amylin deregulate
the cellular proteome, how they impair mitochondrial functions, to which receptors they
bind, aspects of their clearance and how therapeutic strategies exploit the commonalities
between Aβ and amylin. We conclude that research into these two molecules is mutually
beneficial for the treatment of AD and T2DM.
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INTRODUCTION
A rapidly ageing population and the modern sedentary lifestyle,
combined with changes in diet, have to be blamed for the fact that
both Type 2 Diabetes mellitus (T2DM) and Alzheimer’s disease
(AD) are reaching epidemic proportions. World-wide numbers
of patients with diabetes are projected to rise from ∼171 million
at the turn of this century to 366 million by 2030 (Wild et al.,
2004). For comparison, more than 26 million people are cur-
rently living with AD, a number that will quadruple to more than
106 million by 2050 unless strategies are put into place that slow
down, cure or even prevent dementia altogether. Of all dement-
ing disorders, AD is the most common form, comprising 50–70%
of all cases (Ferri et al., 2005). AD is characterized by impaired
memory, visuospatial, language, and executive functions. While
cognitive deficits have traditionally been emphasized in defining
AD, there are a variety of neurobehavioral symptoms also com-
monly associated with the disease, including increased apathy,
agitation, anxiety, and psychiatric symptoms such as delusions or
hallucination (Assal and Cummings, 2002).
In the AD brain, there are two key molecules that undergo
a change in tertiary structure followed by self-association and
deposition, the amyloid-β (Aβ) peptide and tau, a microtubule-
associated protein (Götz and Ittner, 2008). Aβ is proteolytically
derived from the amyloid precursor protein, (APP), and is the
major constituent of Aβ plaques; its size (ranging from 37 to 43
amino acids) is modulated by the thickness of the plasma mem-
brane at the site where the peptide is generated (Area-Gomez
et al., 2012; Winkler et al., 2012). While increased levels are
detrimental, in a physiological context, Aβ has been postulated
to have a role in learning and memory (Morley et al., 2010).
Hyperphosphorylated tau is the major constituent of neurofib-
rillary tangles (Iqbal et al., 2010). Physiological functions of tau
include the binding and stabilization of microtubules in the axon,
and more recently, targeting of the kinase Fyn to the dendrite or
protecting the DNA in the nucleus from various forms of insult
(Ittner et al., 2010; Sultan et al., 2011). What is causing the major-
ity of cases of AD is not known. In the elucidation of disease
mechanisms, rare familial cases were instrumental. In AD, muta-
tions have been identified in the (APP) gene itself, as well as in
the genes that encode presenilin 1 and 2 (PSEN1 and PSEN2),
a protein forming part of the Aβ-generating protease complex.
Frontotemporal lobar degeneration (FTLD) is the second-most
prevalent form of dementia. This complex is classified based on
the proteins that constitute the major brain aggregates. FTLD-
Tau, for example, is characterized by tau aggregates. These are
found in the absence of overt Aβ plaque formation. Again,
there are rare familial forms, for which disease-causing muta-
tions have been identified in the MAPT gene that encodes tau
(Lee et al., 2001). AD is predominantly characterized by memory
loss, whereas FTLD is mainly initiated by behavioral impairment,
with cognitive functions relatively preserved until the disease
becomes more advanced. The neurobehavioral symptoms include
overeating, apathy or euphoria, disinhibition, depression, stereo-
typed behaviors, reduced empathy, and antisocial and aggressive
behaviors. Patients with FTLD also display a variety of cognitive
problems, such as language and memory impairments, and these
are often coupled with a lack of insight into these changes (Neary
et al., 1998). In a significant subset of FTLD, late Parkinsonism
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is found (Lee et al., 2001). To better understand the role of Aβ
and tau in AD and FTLD, experimental mouse models have been
developed, in particular in mice, that reproduce the major aspects
of the neuropathological characteristics of these diseases, along
with memory and motor impairment (Götz and Götz, 2009).
Diabetes mellitus (DM) is subdivided into Type 1 (T1DM) and
Type 2 (T2DM), with the latter accounting for 90% of all cases.
T1DM is characterized by reduced insulin production due to the
destruction of pancreatic islet β-cells, whereas T2DM is charac-
terized by insulin resistance of the target tissue, both of which
results in elevated blood glucose levels. Disease progression cor-
relates well with amylin deposition, a peptide with a central role
in the control of energy homeostasis and satiety that under nor-
mal conditions functions as a synergistic partner of insulin (Lutz,
2010). Interestingly, amylin, that is also known as Islet Amyloid
PolyPeptide (IAPP), forms aggregates already in the pre-diabetic
stage. In doing so it undergoes a change in tertiary structure, sim-
ilar to what is known for Aβ and tau in AD, and the peptide
is finally deposited in β-cells (Hoppener et al., 2000), becom-
ing a characteristic histopathological hallmark lesion of T2DM
(Marzban et al., 2003; Hoppener and Lips, 2006). In humans,
amylin is synthesized with a 22 amino acid signal peptide that is
cleaved off resulting in an inactive 67 amino acid-long propeptide
that is colocalized with insulin in β-cell granules. The mature 37-
amino acid peptide is then generated by proteolysis that employs
a set of proteases. When there is too much amylin this causes an
impairment of glucose-mediated insulin secretion and ultimately
β-cell death, as shown both in vitro and in vivo (Tokuyama et al.,
1997; Hoppener et al., 2000; Hoppener and Lips, 2006).
For T2DM, the discovery of causal genes has followed three
waves as discussed recently (McCarthy, 2010): The first wave
consisted of family-based linkage analysis and focused candidate-
gene studies. This proved effective in identifying the genes
encoding leptin, the leptin receptor and proopiomelanocortin in
extreme forms of early-onset disease that segregate in aMendelian
manner as single-gene inherited disorders. The second wave
of discovery involved a switch to association studies. Common
risk-conferring coding variants were identified in PPARG (encod-
ing peroxisome proliferator-activated receptor gamma), KCNJ11
(potassium inwardly-rectifying channel, subfamily J) and MC4R
(melanocortin-4 receptor). The third wave of discovery has
been driven by systematic, large-scale surveys of the association
between common DNA sequence variants and disease. This iden-
tified an association between T2DM and variants within TCF7L2
(encoding transcription factor 7–like 2, a protein not previ-
ously identified as a candidate) (Grant et al., 2006). TCF7L2 has
subsequently been shown to modulate pancreatic islet function
(Lyssenko et al., 2007). For amylin itself, promoter variants and
specific mutations such as Ser20Gly have been shown to be asso-
ciated with T2DM in some studies, whereas others showed no
association, including one study with over 22,000 participants
(Zee et al., 2011).
Similar to AD, T2DM has been modeled in mice: for exam-
ple, in the ob/ob (leptin knockout) and db/db (leptin receptor
knockout) strains, both of which are insulin resistant (Zhang
et al., 1994; Chen et al., 1996), and in mice that over-express
human amylin in pancreatic islet cells (de Koning et al., 1994;
Janson et al., 1996; Verchere et al., 1996; Westermark et al., 2000).
Breeding of amylin transgenic mice to homozygosity caused
amylin aggregation, β-cell death and diabetes (Janson et al., 1996).
One study showed that transgenic overexpression of fibrillogenic
human amylin in mice caused β-cell degeneration and diabetes
by mechanisms independent of both peripheral insulin resis-
tance and islet amyloid. These findings are consistent with β-cell
death evoked by misfolded but soluble cytotoxic species, such
as those formed by human amylin in vitro (Wong et al., 2008).
Similarly, transgenic rats with β-cell overexpression of human
amylin developed islet amyloid deposits; these were associated
with β-cell death and hyperglycemia (Matveyenko and Butler,
2006a). Diabetes can also be induced in vivo by injecting strep-
tozotocin or by allogeneic expression of major histocompatibility
antigens, and both causes the destruction of β-cells (Götz et al.,
1990; Rees and Alcolado, 2005).
The basis of non-pharmacological DM treatment is diet and
physical activity. About one third of T2DM patients need insulin
to reduce their high blood glucose levels, but they do not crit-
ically depend on the hormone (Harrison et al., 2004; Hussein
et al., 2004). In comparison, the current treatment of AD is symp-
tomatic, slowing the cognitive decline only moderately; FDA-
approved treatments include acetylcholine esterase inhibitors,
and the NMDA glutamate receptor antagonist Memantine that
counteracts excitotoxicity (Ballard et al., 2011).
In conclusion, both T2DM and AD are characterized by insol-
uble protein aggregates with a fibrillar conformation—amylin in
T2DM pancreatic islets, and Aβ and tau in AD brain (Götz et al.,
2009). Amylin aggregation is associated with pancreatic β-cell loss
(although T2DM is believed to arise from insulin resistance in tar-
get organs), whereas Aβ and tangle formation is associated with
neuronal cell loss. β-Cell loss leads to diabetes, nerve cell loss
to dementia. Therefore, T2DM and AD are both conformational
diseases.
COMPARISON OF HUMAN AMYLIN, RAT AMYLIN AND Aβ
Human amylin shares many biophysical and physiological prop-
erties with Aβ (Figure 1A). The two molecules are similar in size
but have little similarities in their primary sequence. However,
different from rat amylin, they fold into similar secondary struc-
tures. In an attempt to convert the 37 amino-acid human amylin
into a less amyloidogenic and hence, less toxic molecule, site-
directed mutagenesis has been performed; this identified residues
13 and 15–17 as an additional aggregation-prone region outside
of the established amyloidogenic region that comprizes residues
20–29 (Fox et al., 2010). Molecular dynamics (MD) simulations
showed that within this region, Pro28 in rat amylin influences
the secondary structure by stabilizing the peptide in a helical
conformation, whereas human amylin (that has a serine at this
position) is highly disordered in the carboxy-terminal region,
presenting transient isolated β-strand conformations. These con-
formational differences are likely responsible for the different
aggregation propensities of the two homologues. As fragment 30–
37 known to aggregate in vitro is identical in both homologues,
it has been argued that the overall sequence must be responsi-
ble for the amyloidogenic properties of human amylin, whereas
the increased helicity in rat amylin due to a proline rather than a
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FIGURE 1 | Shared mode of toxicity of human amylin and Aβ42. (A)
Alignment of the sequences of human (HA) and rat amylin (RA) and
comparison to Aβ42. Shading shows similarities in the rat and human
amylin sequences while important similarities between HA and Aβ42 are
shown in red. (B) HA and Aβ42 both bind to the amylin receptor that is
composed of two molecules of CTR and one molecule of RAMP3. The
small HA-derived peptide AC253 abrogates toxicity of both HA and Aβ42
mediated via the amylin receptor.
serine at position 28 may explain why it is not forming aggre-
gates (Andrews and Winter, 2011). Interestingly, by dissolving
lyophilized rat amylin directly in 20mM Tris-HCl (and not first
in water), rat amylin is in fact capable of forming fibrils. These
structures bind the amyloidogenic dye Congo red indicating that
they are real fibrils. Rat amylin fibrils generated by this method
are toxic to both pancreatic islet and neuronal cell culture sys-
tems, presenting them as a novel anti-amyloid drug discovery tool
(Milton and Harris, 2013).
In amyloidoses, the proteins in question are subjected to
posttranslational modifications. Of the non-enzymatic posttrans-
lational modifications, deamidation of asparagine and glutamine
is the most common. Deamidation can influence the structure,
stability, folding, and aggregation of proteins and has been pro-
posed to play a role in amyloid formation in AD (Shimizu et al.,
2005). While the role deamidation has in AD in forming amy-
loid plaques is not fully understood, one hypothesis is that in
the turn region of Aβ, the Asp23Asn mutation and subsequent
deamidation to isoAsp23 might cause a structural change that
subsequently initiates folding of Aβ into β-sheets (Sargaeva et al.,
2009). By examining the effects of deamidation on the kinetics
of amyloid formation by amylin it was found that deamidation
accelerates amyloid formation and that the deamidated material
can seed amyloid formation of unmodified amylin (Dunkelberger
et al., 2012). This is highly reminiscent of what has been reported
for fibrillar tau that was found to recruit “normal” tau into
aggregates (Guo and Lee, 2011), and interestingly, tau is also a
deamidated protein (Watanabe et al., 1999).
THE AMYLIN RECEPTOR AS A MEDIATOR OF Aβ TOXICITY
For the two amyloidogenic molecules amylin and Aβ, shared and
separate modes of toxicity have been revealed, that are in part
receptor-mediated, with the receptors, at least to some degree,
being shared between the two molecules (Götz et al., 2008). One
of these receptors is the amylin receptor that exists as a dimer-
ized form of the calcitonin receptor (CTR) complexed with the
Receptor activity modifying protein 3 (RAMP3), all of which are
highly expressed in brain (Yamin et al., 1994; Ueda et al., 2001).
This trimeric constellation generates a receptor that binds amylin
with a significantly higher affinity than, for example, Calcitonin
gene related peptide (CGRP) or adrenomedullin (Young, 2005)
(Figure 1B). As discussed below, Aβ toxicity in rat cholinergic
basal forebrain neurons can be blocked by the amylin receptor
antagonist AC187 (Jhamandas and MacTavish, 2004). Another
receptor that is shared between Aβ and amylin is APP, and both
molecules induce APP expression in neuronal and astrocyte cul-
tures (White et al., 2003). The neurotoxicity of the two molecules
is furthermore mediated by specific integrin signaling pathways,
and both can be inhibited with integrin-specific antibodies and
cytochalasin D (Wright et al., 2007).
We found by quantitative proteomics that human amylin and
Aβ deregulate identical mitochondrial proteins supporting the
notion that both amyloidoses have common targets (Lim et al.,
2010). The human amylin receptor mediates the biological effects
of Aβ as shown by the team of Jhamandas et al. (2011), and
in Aβ-forming transgenic mice, the receptor is up-regulated in
brain regions with an elevated amyloid load (Jhamandas et al.,
2011). Patch clamping of human foetal neurons showed that
the electrophysiological effects of Aβ could be blocked with yet
another amylin receptor antagonist, the highly selective 24 amino
acid-long AC253 (Jhamandas et al., 2011). AC253 attenuated
Aβ-mediated caspase-dependent and -independent apoptotic cell
death in human foetal neurons (Figure 1B). In Aβ-forming mice,
both amylin receptor subunits were found up-regulated in brain
areas with a high amyloid burden, suggesting that the latter
may be a signal for up-regulation. In a follow-up study, depres-
sion of hippocampal LTP in Aβ-forming transgenic mice was
found to be mediated through the amylin receptor (Kimura
et al., 2012). Pre-application of AC253 blocked both Aβ- and
human amylin-induced reductions of LTP without affecting base-
line transmission or LTP on its own. The data were complemented
by field EPSP recordings in hippocampal slice cultures of wild-
type mice; in these, Aβ and human amylin depressed the induced
LTP, whereas AC253 enhanced the blunted LTP. Using rat und
human neuronal cultures, application of either Aβ or human
amylin, but not rat amylin, caused a time-dependent increase
of apoptosis markers at the transcriptional level (Jhamandas and
Mactavish, 2012). When AC253 was added following exposure to
Aβ42 or human amylin, this attenuated the induction of several
pro-apoptotic mediators and increased the expression of anti-
apoptotic markers. Together, this suggests that Aβ toxicity is, at
least in parts, mediated by the amylin receptor.
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EFFECTS OF ELEVATED GLUCOSE LEVELS IN ALZHEIMER MODELS
Compelling evidence indicates that excess consumption of sugar-
sweetened beverages and high fat diets play an important role
in the epidemic of obesity, a major risk factor for T2DM, a dis-
ease that has been associated with a higher incidence of AD.
When Aβ plaque-forming transgenic APP/PS1mice were fed with
10% sucrose-sweetened water, compared with control mice fed
with no sucrose added to the water, the sucrose group gained
more body weight and developed glucose intolerance, hyperin-
sulinemia, and hypercholesterolemia. These metabolic changes
were associated with an exacerbation of the memory impair-
ment that characterizes the Aβ-plaque-forming model, and an
up to 3-fold increase in insoluble Aβ levels and its deposition
in the brain. Interestingly, steady-state levels of IDE did not
change, but there was a 2.5-fold increase in brain apolipopro-
tein E levels, a molecule with a central role in sporadic AD (Cao
et al., 2007). In a complementary study, diabetic BBZDR/Wor
rats (T2DM model) were assessed for characteristic AD changes
in their frontal cortices. While neuronal loss was also found in
a model of T1DM (BB/Wor rats), this loss was associated with
a 9-fold increase of dystrophic neurites in the T2DM model.
In addition, different from the T1DM model, protein levels of
APP, β-secretase and Aβ were all increased in the T2DM rats,
as were levels of hyperphosphorylated forms of tau. Collectively,
the data show that accumulation of Aβ and hyperphospho-
rylated tau occurs in experimental diabetes. Interestingly, the
changes were more severe in the T2DM model and appeared to
be associated with insulin resistance and possibly, hypercholes-
terolemia (Li et al., 2007). To address the role of mitochondria
as a functional link between both T2DM and AD, mitochon-
drial functions were assessed in 3xTg-AD mice that present with
a combined Aβ and tau pathology, wild-type mice fed with
20% sucrose-sweetened water for 7 months (T2D mice), and
wild-type mice that received plain water. The study found that
compared to wild-type, mitochondria from 3xTg-AD and T2D
mice presented with a similar impairment of the respiratory
chain and oxidatitive phosphorylation system, a decreased capac-
ity to accumulate calcium, ultrastructural abnormalities, and an
oxidative imbalance, suggesting that the metabolic alterations
associated with diabetes contribute to the development of AD
pathology (Carvalho et al., 2012). In a follow-up study these
mice were analysed behaviorally, by performing the open field,
object recognition, Y-maze, and elevated plus maze tests. In addi-
tion, vascular functions were assessed. The T2D and AD mice
showed comparable behavioral and cognitive impairments, i.e.,
increased fear and anxiety and decreased learning and mem-
ory abilities. Interestingly, both groups of mice presented with
increased plasma markers of endothelial/vascular dysfunction
and permeability of cerebral vasculature, and impaired mito-
chondrial enzymatic activities. Specifically, a decrease in complex
IV activity was found in brain vessels and synaptosomes from
T2D mice, whereas in the 3xTg-AD mice, this decrease was only
seen in synaptosomes. The study furthermore found a significant
increase in Aβ levels in the cortex and hippocampus of T2D mice
supporting the notion that T2DM predisposes to cerebrovascu-
lar alterations, cognitive decline, and the development of AD
(Carvalho et al., 2013). In another study, experimental DM was
induced in FTLD tau transgenic mice and was found to exac-
erbate the tau pathology that characterizes this mouse model of
AD (Ke et al., 2009). Together this shows that altered glucose
levels have a dramatic effect on the tau and Aβ pathology that
characterizes AD.
SIMILAR MECHANISMS OF DEGRADATIONAND CLEARANCE OF Aβ
AND AMYLIN
Levels of Aβ and amylin are determined by the net effect of (1)
their production, and (2) their degradation and clearance. Aβ-
degrading peptidases in vivo are neprilysin (NEP) and Insulin
Degrading Enzyme (IDE). For IDE, additional substrates were
identified, such as amylin or insulin (Qiu and Folstein, 2006).
Enhanced IDE activity correlates well with decreased Aβ levels
in brains of IDE/APP double transgenic mice (Leissring et al.,
2003), and IDE shows a decreased degrading activity of Aβ in
AD compared to control brains (Leissring et al., 2003). In vivo,
IDE substrates compete with each other, and this imbalance
may contribute to the pathogenesis of AD and T2DM (Qiu and
Folstein, 2006). Interestingly, mutations in IDE cause human
T2DM-like symptoms (Farris et al., 2004). As far as neprilysin
is concerned, there are conflicting data as to how this peptidase
may impede islet amyloid formation. One study showed that it
prevented fibrillization of amylin by cleaving it at up to six sites
and that β-cells were protected from toxicity when amylin was
added either exogenously or produced endogenously (Guan et al.,
2012). Another study used mass spectrometry to conclude that
islet amyloid formation was impeded by inhibition of fibril for-
mation rather than by actual peptide degradation (Zraika et al.,
2010). However, irrespective of the mode of action, it is fair to say
that boosting the activities of these clearing enzymes is likely to
be a valid strategy in reducing the pathological changes in both
AD and T2DM.
TOXICITY OF Aβ AND AMYLIN
Similar to Aβ, amylin can induce apoptotic cell-death (Hiddinga
and Eberhardt, 1999). When we incubated hippocampal and cor-
tical primary neurons with either non-aged or aged preparations
of Aβ42 and human amylin, based on the aggregation state of rat
and human amylin as well as that of Aβ42, we expected that the
two latter molecules would exert a similar degree of toxicity. We
found that in 20DIV (days in vitro) hippocampal cultures, non-
aged Aβ42 was able to illicit toxicity at 5μM, and this effect was
enhanced by aging of Aβ42, whereas aged preparations of Aβ42
were already significantly toxic at 0.5μM, compared to the PBS
control (Lim et al., 2008). We observed a similar dose-dependency
in the human amylin-treated cells, revealing enhanced neurotox-
icity of aged compared to non-aged human amylin preparation.
Different from human amylin and Aβ42, rat amylin was not toxic
to hippocampal neurons at either concentration tested. This sug-
gested to us that a specific receptor-peptide interaction may be
involved in neurotoxicity. Our data is consistent with studies in
HeLa and β-cells in which human, but not non-amyloidogenic
mouse amylin induced an aggregation state-dependent apoptosis
(Ritzel and Butler, 2003). When we exposed cortical neurons to
either Aβ42 or human amylin, we found that, different from hip-
pocampal cultures, these were generally less susceptible. Similar
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to Aβ42, aging of human amylin enhanced its neurotoxic prop-
erties to a degree similar to what was found for hippocampal
cultures. Together, this suggests that hippocampal neurons are
more susceptible to the neurotoxic effects of both human amylin
and Aβ42, indicating selective vulnerability. We also found that
rat amylin, which does not form fibrils, while not being toxic
to hippocampal neurons, surprisingly, it was to cortical neurons
(Lim et al., 2008).
While it is still not fully clear to which cellular components
Aβ binds in order to exert its toxicity it appears unlikely that
there are just one or two cognate receptors, or that there are
only one or two assembly forms of the peptide that can induce
neuronal dysfunction; in fact, Aβ is likely to bind to different
components of neuronal and non-neuronal plasma membranes
and thereby induces complex patterns of synaptic dysfunction
and network disorganization (Mucke and Selkoe, 2012). As far
as amylin is concerned, this molecule binds to receptors (such as
the amylin receptor) but at the same time, using a combination of
x-ray diffraction and circular dichroism, it was found that the β-
aggregates of amylin can also bind directly on the surface of lipid
bilayers, without penetrating into the bilayer structure (Lee et al.,
2012).
PROTEOMICS SHEDS LIGHT ON AMYLIN’S AND Aβ’S DAMAGING
EFFECTS ON MITOCHONDRIAL FUNCTIONS
In our hands, assessing changes to the proteome in the pres-
ence of protein aggregates composed of either Aβ, amylin, or
tau has been particularly insightful. We entered the field by
performing a proteomic analysis on fractionated brain extracts
from tangle-forming P301L tau mutant pR5 mice, a model
of the tau pathology of FTLD and AD (David et al., 2005).
This approach identified mainly metabolism-related proteins
including mitochondrial respiratory chain complex components,
antioxidant enzymes, and synaptic proteins as being deregulated.
As this indicated that only a limited number of cellular func-
tions were impaired, this prompted us to functionally validate
these proteomics findings. We were able to demonstrate a mito-
chondrial dysfunction in the pR5 mice, associated with higher
levels of reactive oxygen species (ROS) and an up-regulation of
antioxidant enzymes. Furthermore, the pR5 mitochondria dis-
played an increased vulnerability toward fibrillar Aβ peptide
(David et al., 2005). We found that tau mainly impairs com-
plex I of the respiratory chain, whereas Aβ (as shown in Aβ
plaque-formingAPP transgenicmice)mainly impairs complex IV
(Hauptmann et al., 2008).
In many cellular systems including pancreatic β-cells it has
been shown that nutrient fluctuations and insulin resistance
increase proinsulin synthesis in β-cells beyond the capacity for
folding of nascent polypeptides within the endoplasmic reticu-
lum (ER) lumen, thereby disrupting ER homeostasis and trig-
gering the “unfolded protein response (UPR)” (Song et al.,
2008). This happens in part through the UPR-induced tran-
scription factor C/EBP homologous protein (CHOP). In both
genetic and diet-induced models of insulin resistance, CHOP
deficiency improved β-cell ultrastructure and promoted cell sur-
vival. In addition, isolated islets from Chop knockout mice dis-
played increased expression of UPR (BiP, Grp94, Fkbp11, and
p58IPK) and oxidative stress response genes (Sod1, Sod2, Gpx1,
Pparg, and Ucp2), and reduced levels of oxidative damage. These
findings suggest that CHOP is a fundamental factor that links
protein misfolding in the ER to oxidative stress and apopto-
sis in β-cells under conditions of increased insulin demand
(Song et al., 2008). Transgenic expression of human amylin in
islets induces β-cell apoptosis (Huang et al., 2007). Our pro-
teomic and biochemical analysis of Aβ-injected pR5 mice, a
model combining the tau and Aβ pathology of AD (Götz et al.,
2001), also suggests an impaired “unfolded protein response”
due to protein aggregation (David et al., 2006). Among the
up-regulated proteins with roles in protein folding and stress
response were ICDH, the proteasome subunit alpha type 3, and
the mitochondrial Grp75. Down-regulated were several mem-
bers of the peroxiredoxin family. Together, this supports the
notion of an altered “unfolded protein response” in both AD and
T2DM.
Regarding Aβ’s and amylin’s toxicity, there is another level
of complexity (Fodero-Tavoletti et al., 2011). In the case of
Aβ, the peptide’s size ranges from 38 to 43 amino acids; fur-
thermore, Aβ is pyroglutaminated at its amino-terminus, which
increases its toxicity (Schlenzig et al., 2012). Furthermore, Aβ
and amylin assume various aggregation states that range from
monomeric to oligomeric to fibrillar (Lesne et al., 2006). We
found that different from monomeric Aβ, both fibrillar and
oligomeric forms cause mitochondrial dysfunction (Eckert et al.,
2008). For T2DM, evidence is accumulating that it is oligomeric
amylin that participates in β-cell apoptosis, while the degree
of toxicity exerted by fibrillar species is less clear (Matveyenko
and Butler, 2006b; Lin et al., 2007). As the accumulation of
monomeric species precedes the formation of oligomeric and
fibrillar species (that are in an equilibrium), from a therapeu-
tic point of view the safest strategy might be to reduce total
amyloid levels rather than depleting distinct pools such as the
oligomers.
At a proteomic level, T2DMandAD share a remarkably similar
profile. This is impressively illustrated by an analysis of pancreatic
islets that identified several novel proteins that are also associ-
ated with AD pathogenesis (Nicolls et al., 2003). Interestingly, in
a proteomic study using Aβ-injected tau transgenic pR5 brains,
we identified a significant subset of “islet” proteins to be dereg-
ulated upon Aβ injection, such as GRP78, valosin-containing
protein, calreticulin, the HSP family or peroxiredoxin (David
et al., 2006). Similarly, in the insoluble “formic acid” fraction of
Aβ-treated P301L tau-transfected cells, we identified Insulin-like
growth factor binding protein 2 precursor (IGFBP-2) as being
up-regulated, again pointing at similarities between DM and AD.
Together with work published by others (Hickey et al., 2009),
this implies that similar proteins and pathways are activated by
amylin and Aβ, respectively, in either pancreatic islets (T2DM) or
neurons (AD).
To determine whether the same proteins or protein cate-
gories are deregulated by Aβ42 and human amylin, we performed
iTRAQ labeling followed by quantitative mass spectrometry of
human SH-SY5Y neuroblastoma cells that had been treated
for 5 days with aged preparations of Aβ42, human amylin,
rat amylin and the respective vehicle controls (Lim et al., 2010).
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When rigorous criteria were applied, Aβ42 significantly dereg-
ulated 69 proteins, whereas human amylin deregulated 49
proteins. Remarkably, of these, 31 were shared in both the
Aβ42 and human amylin treatment groups. [Treatment with
the non-amyloidogenic rat amylin identified only five pro-
teins, of which one (midkine) was shared with human amylin].
Of the proteins that were significantly altered in both the
Aβ42 and human amylin groups, for all but one protein,
the direction of change was the same. Significantly dereg-
ulated proteins were sorted manually using Gene Ontology
(GO) into their respective categories. The functional group
with the largest number of proteins that was significantly
altered in response to both peptide treatments was asso-
ciated with mitochondrial functions/energy metabolism and
antioxidant activities, representing more than 25% of all
significantly deregulated proteins. While the majority of mito-
chondrial/metabolic proteins was down-regulated, antioxidant
proteins were mostly up-regulated, suggesting a typical cellu-
lar response to oxidative stress. Functional validation revealed
that mitochondrial complex IV activity was significantly reduced
after treatment with either Aβ42 or human amylin, as was
mitochondrial respiration. In comparison, complex I activity
was only reduced after treatment with human amylin. Aβ42
and human amylin, but not rat amylin, induced significant
increases in the generation of ROS. Co-incubation of Aβ42
and human amylin did not produce an augmented effect in
ROS production, again suggesting common toxicity mechanisms
(Lim et al., 2010).
Interestingly, mitochondria represent not only an indirect
target; instead, in several studies Aβ has been localized to mito-
chondria (Caspersen et al., 2005) and shown to act directly on
these organelles (Lustbader et al., 2004; Crouch et al., 2005)
whose function it impairs (Keil et al., 2004; David et al., 2005;
Eckert et al., 2008; Rhein et al., 2009). Among the mitochon-
drial proteins to which Aβ has been shown to bind is the
enzyme amyloid-binding alcohol dehydrogenase (ABAD) (Yan
et al., 1997; Takuma et al., 2005). ABAD converts estradiol
to estrone, and its levels are critical as optimal estradiol lev-
els are an important determinant of neuronal survival (Yang
et al., 2007). To directly determine whether Aβ-induced tox-
icity is mediated by ABAD inhibition and to establish estra-
diol levels as a suitable readout, we employed the use of the
ABAD inhibitor AG18051 in vitro (Kissinger et al., 2004). We
found that AG18051 partially blocked the Aβ-ABAD interac-
tion in a pull-down assay while it also prevented the Aβ42-
induced down-regulation of ABAD activity, as measured by
levels of estradiol, a known hormone and product of ABAD
activity. Furthermore, AG18051 significantly reduced Aβ42 tox-
icity, as measured by LDH release and ROS levels in SH-SY5Y
human neuroblastoma cells. Guided by our previous finding
of shared aspects of the toxicity of Aβ and human amylin,
we determined in SH-SY5Y cells whether AG18051 would also
confer protection from human amylin toxicity. We found, how-
ever, that the inhibitor conferred only partial protection from
human amylin toxicity indicating partly shared yet still distinct
patho-mechanisms of the two amyloidogenic agents (Lim et al.,
2011).
COMMON TREATMENT STRATEGIES?
The biochemical commonalities between T2DM and AD would
imply that common treatment strategies could be pursued.
Among the potentially suitable strategies are vaccinations that
have been successful in mice, targeting both Aβ and tau (Götz
et al., 2012). Unfortunately, the clinical trials using anti-Aβ anti-
bodies basically failed to meet their primary end points (Karran,
2012), while tau-based strategies have not yet been tested in a clin-
ical setting. These failures are disappointing and bear the danger
that the pharmaceutical industry will gradually retreat, however,
there is a lot that can be learned from these failures, such as
antibody dosing, design and route of administration, and it is
certainly too early to give up. Because the immune response to
amyloid oligomers is largely directed against generic epitopes that
are common to amyloid oligomers of many different proteins and
independent of a specific amino acid sequence, it is even possi-
ble to use an oligomer with a random sequence (3A) that reacts
with the oligomer-specific antibody A11 as an effective immuno-
gen (Rasool et al., 2012). Aβ plaque-forming Tg2576 mice were
immunized with an Aβ oligomer, a human amylin oligomer, Aβ
fibrils, and 3A oligomers. Although the human amylin oligomer
and 3A oligomer mimics-vaccinated mice showed a relatively low
titer as compared to the Aβ oligomer- and Aβ fibril-vaccinated
groups, they retained their efficacy in preventing cognitive deficits
and amyloid deposition. The data would suggest that an effec-
tive targeting of toxic species rather than the overall extent of
the elicited immune response may be relevant (Rasool et al.,
2012).
The effectiveness of antioxidants in modulating oxidative
stress in AD has been widely explored. The antioxidants that
have been shown to protect against Aβ-induced oxidative stress
include vitamin E, various polyphenols, such as quercetin and
resveratrol, α-lipoic acid, and curcumin (a planar biphenolic
compound found in the Indian spice turmeric) (Pocernich et al.,
2011). Curcumin has been shown to reduce Aβ pathology in
various mouse models (Yang et al., 2005), by a mechanism that
includes attenuating the maturation of APP in the secretory path-
way (Zhang et al., 2010). Less data are available on the effect of
curcumin in ameliorating the toxic effects of amylin. In a recent
study it was found that curcumin alters amylin’s misfolding and
protects from cellular toxicity at physiologically relevant concen-
trations. Using electron paramagnetic resonance spectroscopy,
thioflavinT fluorescence and electron microscopy, curcumin was
found to significantly reduce amylin fibril formation and aggre-
gate formation by altering its morphology and structure. Yet β-
cells were protected from exogenous amylin toxicity by curcumin
only within a relatively narrow concentration range, because
curcumin became cytotoxic at micromolar concentrations. In
other models, curcumin failed to protect β-cells from amylin-
induced apoptosis leading the authors to suggest that without
further modification, the compound is unlikely to be therapeu-
tically useful in protecting β-cells in T2DM from destruction
(Daval et al., 2010). Another study found that curcumin delayed
the self-assembly of amylin into NMR-invisible assemblies
(Sparks et al., 2012). Interestingly, when a double N-methylated
and hence conformationally constrained analogue of amylin
was employed this blocked the cytotoxic self-assembly of
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Aβ (Rezaei-Ghaleh et al., 2011). Finally, using HEK293 cells that
stably express the amylin receptor, both Aβ and human amylin
were found to induce cell death at low micromolar concentra-
tions. In the presence of human amylin, however, the effect of
Aβ42 was occluded, suggesting a shared mechanism of action
between the two peptides. Moreover, the amylin receptor antag-
onist AC253 blocked toxic responses including cell death, in
response to an activation of the amylin receptor by either human
amylin itself, Aβ42, or upon their co-application. This suggests
that the amylin receptor may represent a novel therapeutic target
for the development of compounds in the treatment of neurode-
generative conditions such as AD (Fu et al., 2012). What might
potential side effects be of amylin receptor antagonists? Since
the amylin receptor regulates food intake and body weight and
the amylin agonist davalintide (AC2307), a novel amylin-mimetic
peptide, has been found to reduce food intake and increase weight
loss (Mack et al., 2010), by extrapolation, amylin antagonists may
cause increases in weight due to increased food uptake. To our
knowledge, however, this has not been observed in the animal
studies that either tested AC253 or related antagonists.
In conclusion research into both amylin and Aβ has proven
mutually beneficial in designing treatment strategies that hope-
fully benefit both AD and T2DM.
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